I1LM34 Stock Overview
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Illumina, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$96.74 |
| 52 Week High | US$178.38 |
| 52 Week Low | US$96.30 |
| Beta | 1.17 |
| 1 Month Change | -14.19% |
| 3 Month Change | n/a |
| 1 Year Change | -23.83% |
| 3 Year Change | -70.19% |
| 5 Year Change | -61.49% |
| Change since IPO | -63.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| I1LM34 | BR Life Sciences | BR Market | |
|---|---|---|---|
| 7D | 0.5% | 0% | 0% |
| 1Y | -23.8% | 0% | 0% |
Return vs Industry: I1LM34 underperformed the BR Life Sciences industry which returned -13.3% over the past year.
Return vs Market: I1LM34 underperformed the BR Market which returned -3.2% over the past year.
Price Volatility
| I1LM34 volatility | |
|---|---|
| I1LM34 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in BR Market | 0% |
| 10% least volatile stocks in BR Market | 0% |
Stable Share Price: I1LM34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine I1LM34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 9,000 | Jacob Thaysen | www.illumina.com |
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.
Illumina, Inc. Fundamentals Summary
| I1LM34 fundamental statistics | |
|---|---|
| Market cap | R$79.35b |
| Earnings (TTM) | -R$6.99b |
| Revenue (TTM) | R$24.98b |
3.2x
P/S Ratio-11.4x
P/E RatioIs I1LM34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I1LM34 income statement (TTM) | |
|---|---|
| Revenue | US$4.37b |
| Cost of Revenue | US$1.38b |
| Gross Profit | US$2.99b |
| Other Expenses | US$4.21b |
| Earnings | -US$1.22b |
Last Reported Earnings
Dec 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.72 |
| Gross Margin | 68.37% |
| Net Profit Margin | -27.97% |
| Debt/Equity Ratio | 83.8% |
How did I1LM34 perform over the long term?
See historical performance and comparisonDividends
87.4%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 07:08 |
| End of Day Share Price | 2025/03/19 00:00 |
| Earnings | 2024/12/29 |
| Annual Earnings | 2024/12/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Illumina, Inc. is covered by 54 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| James Francis Mainwaring | Atlantic Equities LLP |
| Catherine Ramsey Schulte | Baird |